Abstract
Personalized medicine is defined by the author as an integration of various biotechnologies to provide treatment best suited for a patient taking into consideration genomic as well as non-genomic factors. This chapter focuses on the role of neurogenomics in the development of personalized neurology, and the relationship to other relevant “omics” such as neuroproteomics is pointed out. Several of the genes relevant to neurological disorders have been sequenced, and their relation to various neurological disorders is under investigations. Genomic technologies may play a role in molecular diagnostics, biomarkers, as well as treatment of neurological disorders. The role of pharmacogenomics and pharmacogenetics in pharmacotherapy of various diseases is also discussed.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Biffi A, Anderson CD, Jagiella JM, et al. APOE genotype and extent of bleeding and outcome in lobar intracerebral haemorrhage: a genetic association study. Lancet Neurol 2011;10:702–9.
Billeci AM, Agnelli G, Caso V. Stroke pharmacogenomics. Expert Opin Pharmacother. 2009;10:2947–57.
Chasman DI, Schürks M, Anttila V, et al. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat Genet. 2011;43:695–8.
Comabella M, Vandenbroeck K. Pharmacogenomics and multiple sclerosis: moving toward individualized medicine. Curr Neurol Neurosci Rep. 2011;11:484–91.
Davidson J, Cusimano MD, Bendena WG, et al. Post-traumatic brain injury: genetic susceptibility to outcome. Neuroscientist. 2014;pii: 1073858414543150.
Do CB, Tung JY, Dorfman E, et al. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson’s disease. PLoS Genet. 2011;7:e1002141.
Dreses-Werringloer U, Lambert JC, Vingtdeux V, et al. A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer’s disease risk. Cell. 2008;133:1149–61.
Falkenberg VR, Gurbaxani BM, Unger ER, Rajeevan MS. Functional genomics of serotonin receptor 2A (HTR2A): interaction of polymorphism, methylation, expression and disease association. Neuromolecular Med. 2011;13:66–76.
Feng JF, Zhang KM, Jiang JY, et al. Effect of therapeutic mild hypothermia on the genomics of the hippocampus after moderate traumatic brain injury in rats. Neurosurgery. 2010;67:730–42.
Gotovac K, Hajnšek S, Pašić MB, et al. Personalized medicine in neurodegenerative diseases: how far away? Mol Diagn Ther. 2014;18:17–24.
Greenberg DA, Cayanis E, Strug L, et al. Malic enzyme 2 may underlie susceptibility to adolescent-onset idiopathic generalized epilepsy. Am J Hum Genet. 2005;76:139–46.
Grover S, Kukreti R. A systematic review and meta-analysis of the role of ABCC2 variants on drug response in patients with epilepsy. Epilepsia. 2013;54:936–45.
Habek M, Borovecki F, Brinar VV. Genomics in multiple sclerosis. Clin Neurol Neurosurg. 2010;112:621–4.
International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476:214–9.
Jahanshad N, Rajagopalan P, Hua X, et al. Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity. Proc Natl Acad Sci U S A. 2013;110:4768–73.
Jain KK. Textbook of personalized medicine. 2nd ed. New York: Springer; 2015.
Kappos L, Achtnichts L, Dahlke F, et al. Genomics and proteomics: role in the management of multiple sclerosis. J Neurol. 2005;252 Suppl 3:iii21–7.
Kearney JA. Advances in epilepsy genetics and genomics. Epilepsy Curr. 2012;12:143–6.
Oertel B, Lötsch J. Genetic mutations that prevent pain: implications for future pain medication. Pharmacogenomics. 2008;9:179–94.
Oksenberg JR. Decoding multiple sclerosis: an update on genomics and future directions. Expert Rev Neurother. 2013;13(12 Suppl):11–9.
Pasinetti GM, Fivecoat H, Ho L. Personalized medicine in traumatic brain injury. Psychiatr Clin North Am. 2010;33(4):905–13.
Rakvåg TT, Ross JR, Sato H, et al. Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol Pain. 2008;4:64.
Reiman EM, Webster JA, Myers AJ, et al. GAB2 Alleles Modify Alzheimer’s Risk in APOE varepsilon4 Carriers. Neuron 2007;54:713–20.
Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39:168–77.
Sadhasivam S, Chidambaran V, Olbrecht VA, et al. Genetics of pain perception, COMT and postoperative pain management in children. Pharmacogenomics. 2014;15:277–84.
Smith AK, Fang H, Whistler T, et al. Convergent genomic studies identify association of GRIK2 and NPAS2 with chronic fatigue syndrome. Neuropsychobiology. 2011;64:183–94.
Stamer UM, Stuber F. Genetic factors in pain and its treatment. Curr Opin Anaesthesiol. 2007;20:478–84.
Stein MA, Waldman ID, Sarampote CS, et al. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology. 2005;30:1374–8.
Vernon SD, Reeves WC. The challenge of integrating disparate high-content data: epidemiological, clinical and laboratory data collected during an in-hospital study of chronic fatigue syndrome. Pharmacogenomics. 2006;7:345–54.
Yoshida S, Sugawara T, Nishio T, Kaneko S. Personalized medicine for epilepsy based on the pharmacogenomic testing. Brain Nerve. 2011;63:295–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Jain, K.K. (2015). Role of Neurogenomics in the Development of Personalized Neurology. In: Jain, K. (eds) Applied Neurogenomics. Neuromethods, vol 97. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2247-5_6
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2247-5_6
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2246-8
Online ISBN: 978-1-4939-2247-5
eBook Packages: Springer Protocols